Answers are grounded in this paper and cite their sources.
This study is the first to gather information directly from patients with TGCT regarding their symptom experiences. Pain, stiffness, and physical functioning are important treatment outcomes in patients with TGCT. We have identified content-valid PRO measures of these concepts, which are included in an ongoing Phase III TGCT clinical trial with pexidartinib (PLX3397) (NCT02371369).
No takes yet. Share an insight, caveat, or question.
Gelhorn et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: